436results about "Viruses" patented technology

To provide universal antigen presenting cells.SOLUTION: Also provided herein are methods of expanding immune cells using the UAPCs and methods for the treatment of a disease, such as cancer, using the expanded immune cells.SELECTED DRAWING: Figure 1A

To provide immunotherapy that prevents or minimizes the failure of immunotherapy treatment due to the emergence of antigen-loss escape mutations in cancer cells, etc. [Solution] A bispecific chimeric antigen receptor comprising (a) an antigen-specific target-directed region containing an antigen-specific single-chain Fv(scFv) fragment that binds to at least two different antigens, (b) an extracellular spacer domain, (c) a transmembrane domain, (d) at least one costimulatory domain, and (e) an intracellular signaling domain, which is to be co-expressed with a therapeutic regulatory substance such as truncated epidermal growth factor receptor (EGFRt).

The disclosure relates to the technical field of vaccine preparation, and in particular to an immune-enhancing delivery system formed by targeted antigen delivery by CCL11. The system further enhances immunogenicity by fusing a chemokine CCL11 with a corresponding antigen molecule, and adding a T2 label at a terminal of the antigen molecule. The system can be a nucleic acid vector or a fusion protein or the like to be applied to prevention and / or treatment of diseases caused by a corresponding antigen. According to the present invention, by utilizing a chemotactic binding capacity of CCL11 with a surface receptor of an immune cell such as a DC, different antigen proteins are transported to the surface of the DC, so that the efficiency of phagocytosis, processing and presentation of the DC on various antigen proteins is improved, and the effect of preventing and treating related diseases is improved.

The present invention relates to a recombinantly constructed protein that is useful for analytical assay, particularly for determining the presence of rhabdovirus specific antibody in biological samples obtained from individuals.More specifically, the present invention relates to a polypeptide that comprises the ectodomain of rhabdovirus glycoprotein and the heterologous multimerization domain connected to said ectodomain.In one example, there is provided a fusion protein of formula xyz (wherein x consists of or comprises the ectodomain, which may not contain furin cleavage site, y is a linker site, and z is the heterologous multimerization domain that may be selected from the group consisting of immunoglobulin sequence, coiled coil sequence, streptavidin sequence, fibritin sequence and avidin sequence).

Disclosed herein are antibodies and antigen-binding fragments thereof that specifically bind human CD4. Also disclosed are fusion proteins comprising Paramyxoviridae glycoprotein G and CD4 antibodies for targeting and transducing cells expressing CD4. Viral vectors and other compositions containing the fusion proteins, as well as methods of using the fusion proteins, are also disclosed.

Provided herein are compositions, systems, kits, and methods for immunizing a subject against severe fever with thrombocytopenia syndrome virus (SFTS virus) using a composition comprising: i) a plurality of nanoparticles self-assembled from a plurality of fusion proteins comprising a) at least a portion of a ferritin protein, and b) at least a portion of an immunogenic protein comprising at least a portion of the SFTS virus Gn and / or Gc envelope glycoprotein; or ii) a polynucleotide encoding the fusion protein (e.g., an mRNA sequence present in a lipid nanoparticle).

The present disclosure relates to a method for the production of CD4 + CD4 produced by genetically modifying T cells IL-10 / CAR Provide cell populations (autologous or allogeneic single donor and allogeneic polydonor). In addition, CD4 IL-10 / CAR Methods for generating CD4 cells and for immune tolerance IL-10 / CAR Methods of using the cells to treat GvHD, cell and organ transplantation, cancer, and other autoimmune and inflammatory disorders are provided.

Provided are an antibody specifically binding to CD276 and use thereof. Specifically provided are a CD276 antibody or an antigen binding fragment thereof, and the like. Also provided are a polynucleotide encoding the CD276 antibody, a nucleic acid construct comprising the polynucleotide, an expression vector comprising the nucleic acid construct, a preparation method and a transformed cell thereof. The provided CD276 antibody can bind to CD276 protein at a high affinity and a high specificity, can be prepared into a target recognition domain of CAR-T cells, and can also be prepared into a bispecific T-cell engager (BiTE) to exert an anti-tumor effect for preventing or treating cancers.

Provided are therapeutic agent including nucleic acid and CAR-modified immune cell and the use thereof. The therapeutic agent comprises first composition and second composition, the first composition comprises a nucleic acid having a labeling polypeptide coding sequence for being introduced into a tumor cell and / or a cancer cell; the labeling polypeptide has an extracellular antigen determining region, a spacer portion, a transmembrane portion that are operatively linked, which can be expressed to form modification on the surface of the tumor cell and / or cancer cell; the extracellular antigen determining region comprises one or more epitope polypeptides; wherein, amino acid sequences of proteins on cell membrane or secreted proteins of mammal do not comprise the epitope polypeptide amino acid sequence in the natural state; the second composition comprises chimeric antigen receptor modified immune cell which specifically recognize and bind to the extracellular antigen determining region. The therapeutic agent achieves synergistic therapeutic effect.

The invention provides a method for introducing an exogenous substance into a cell, the method comprising exposing the cell to a transient pressure reduction in the presence of the exogenous substance. Apparatus for performing the method of the invention is also provided.

The present invention pertains to: a granzyme B variant having enhanced protease activity and / or enhanced tolerance against an inhibitory factor; a polynucleotide encoding the granzyme B variant; a cell expressing the granzyme B variant; a pharmaceutical composition comprising the cell expressing the granzyme B variant; and a pharmaceutical composition comprising the granzyme B variant. In some embodiments, the pharmaceutical composition can be used in combination with a cell expressing a chimeric receptor and / or an antigen-binding molecule.

When expressed recombinantly on the T cell surface, HLA-A * Provided herein are T cell receptors (TCRs) capable of recognizing the MAGE-B2 derived peptide GVYDGEEHSV (SEQ ID NO: 1) when presented by 02:01 sufficiently to activate recombinant T cells. Certain TCRs provided herein are also capable of recognizing the MAGE-A4 derived peptide GVYDGREHTV (SEQ ID NO: 2) sufficiently to activate recombinant T cells. Importantly, the exemplary TCRs provided herein have been thoroughly screened for lack of cross-reactivity with similar peptides that may be presented by normal cells or tissues, and for alloreactivity.

To provide methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions comprising the same and reaction mixtures.SOLUTION: A method for expanding and / or activating a population of immune cells (e.g., immune effector cells) includes introducing a nucleic acid encoding a first chimeric antigen receptor (CAR) molecule into an immune cell population, under conditions suitable for transient expression of the CAR molecule, thereby producing a first CAR-expressing cell population, where the CAR molecule comprises an antigen binding domain of an antigen molecule; and contacting the first CAR-expressing cell population with a ligand of the CAR antigen binding domain selected from a cognate antigen molecule (e.g., a recombinant antigen) or an anti-idiotypic antibody molecule, under conditions such that immune cell expansion and / or activation occurs, thereby producing an expanded and / or activated immune cell population.SELECTED DRAWING: None

To provide a gene modified cell including a modified T cell receptor (TCR) alpha steady region gene in a genome of the gene modified cell.SOLUTION: There is provided a gene modified cell including in a genome thereof, a modified human T cell receptor (TCR) alpha steady region gene, the modified human TCR alpha steady region gene includes, from 5' to 3', a 5' region of the human TCR alpha steady region gene, an exogenous polynucleotide, and a 3' region of the human TCR alpha steady region gene. The modified human TCR alpha steady region gene is a gene modified human T cell or a gene modified cell derived from a human T cell, and in comparison with a non-modified control cell, expression of an endogenous TCR on a cell surface is suppressed.SELECTED DRAWING: Figure 1

This disclosure provides methods and constructs for improving the persistence or function of immune cells. In particular, the methods or constructs include a mutant interleukin-15 (IL-15) transgene under the control of a constitutive or inductive promoter to enhance the function of immune cells. The mutant IL-15 is modified to focus signaling to cells expressing IL-15Rα and / or signaling complexes containing IL-15Rα. More specifically, this disclosure provides methods and constructs for enhancing the function of immune cells by enhancing immune cell proliferation, reducing antigen-independent interferon-gamma (IFNγ) release, and suppressing tumor growth and unregulated immune cell proliferation.

To provide AAV having modified transduction ability, the AAV including in its structure, various kinds of transducing genes including a clinically important transducing gene for a patient who requires a transducing gene.SOLUTION: There are provided: an isolation modification VP1 protein of an adeno-associated virus serotype 5 (AAV5) capsid, including one or more amino acid replacements for improving transduction efficiency, relative to VP1 protein of a wild type AAV5 capsid; and capsid and vector based on the isolation modification VP1 protein.SELECTED DRAWING: None

The process provided in this invention transfects primary cells with gene editing reagents using a high-volume gas-permeable cell culture device and a flow-through electroporation device under conditions that improve gene editing performance, cell yield, and drug (DP) quality characteristics for cell therapy applications. As demonstrated in the examples, primary cells edited according to the process provided herein achieved improved double-strand break (DSB) formation rates, increased frequency of homology-directed repair (HR) and non-homologous end joining (NHEJ) combinations, increased frequency of bi-allelic and mono-allelic HR events, improved cell viability, proliferative capacity, and cell fitness after gene editing, and reduced manufacturing time.

The invention relates to an immune system humanized mouse biological system for preparing a fully humanized monoclonal antibody and a method for preparing the fully humanized monoclonal antibody. The method comprises the following steps: using a constructed immune system humanized mouse and a VLP chimeric antigen; the HSC immune system humanized mouse is an immunodeficient mouse transplanted with human immune cells, the human immune cells are reconstructed, and antigen-specific B cells and fully humanized antibodies can be generated in the immune system humanized mouse by using a VLP chimeric antigen without firstly activating DC and antigen-specific T cells. In addition, by coupling a VLP antigen and a target antigen, a specific B cell and a fully human antibody of any target can be generated.

Provided herein are polycistronic constructs for the co-expression of synthetic cytokine receptor complexes and chimeric antigen receptor systems, as well as vectors, e.g., viral vectors, containing the constructs, cells containing the constructs, and methods of using the constructs.

Compositions, methods, and systems for selecting polynucleotides for their activity as neuron-specific transcription factors are disclosed herein. [Solution] The system of the present invention may include a library of polynucleotides encoding reporter proteins and panneuronal markers, Gas proteins, and guide RNAs (gRNAs) that target putative transcription factors. A method for screening neuron-specific transcription factors is further provided.

A method for treating patients who may have developed or already have neutralizing antibodies against gene therapy vectors by administering a protease that cleaves peptide bonds present in immunoglobulins, or by administering a glycosidase. [Solution] A method for treating a subject requiring treatment for a disease caused by loss of protein function or activity, comprising: (a) administering a recombinant viral vector to the subject containing a heterologous polynucleotide encoding a protein or peptide that provides or supplements the function or activity of a protein; and (b) administering to the subject an amount of protease or glycosidase effective in degrading, digesting and / or inhibiting or reducing the effector function of an antibody bound to the protein or peptide encoded by the recombinant viral vector and / or heterologous polynucleotide.

An object of the present invention is to provide a therapeutic or preventive agent for myocardial infarction, cardiac fibrosis, or heart failure using Htra3 as a therapeutic target. According to the present invention, there is provided a therapeutic or preventive agent for myocardial infarction, cardiac fibrosis, or heart failure containing at least one of (a) serine protease HtrA3, (b) a nucleic acid encoding HtrA3, (c) an expression vector containing a nucleic acid encoding HtrA3, (d) a cell transformed with the nucleic acid or the expression vector, and (e) an antibody that binds to serine protease HtrA3.

This disclosure describes an artificial expression construct containing a PD1:cytokine chimeric transgene under the control of an inducible promoter. The artificial expression construct of this disclosure can be used to enhance the function of immune cells (e.g., CAR-T cells) that have recombinant receptors. The inducible PD1:cytokine chimeric transgene disclosed herein enhances the potency of immune cells (e.g., CAR-T cells) that have recombinant receptors, thereby enhancing killing, proliferation of immune cells, and / or cytokine production.

The present disclosure provides isolated peptides derived from hepatitis B virus (HBV), peptide-based molecules (e.g., peptide-MHC (pMHC) complexes), polynucleotides and vectors encoding these peptides or peptide-based molecules, pharmaceutical compositions (e.g., vaccine compositions), and uses thereof for the treatment or prevention of HBV infection and / or diseases induced by HBV. The present disclosure also provides binding moiety structures that bind to the peptides or peptide-based molecules disclosed herein, and uses thereof for the treatment or prevention of HBV infection and / or diseases induced by HBV. The present disclosure further provides methods and systems for identifying immunogenic virus-derived peptides.

The present invention provides a bispecific chimeric antigen receptor targeting BCMA-CD19 and its use. The bispecific chimeric antigen receptor comprises an extracellular antigen recognition domain, the extracellular antigen recognition domain comprises an anti-BCMA extracellular antigen recognition domain and an anti-CD19 extracellular antigen recognition domain, the anti-BCMA extracellular antigen recognition domain comprises a BCMA VH and a BCMA VL, the amino acid sequences of the BCMA VH complementarity determining regions CDR1, CDR2 and CDR3 comprise the amino acid sequences represented by SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, and the amino acid sequences of the BCMA VL complementarity determining regions CDR1, CDR2 and CDR3 comprise the amino acid sequences represented by SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6, respectively.

This document relates to methods and materials involved in treating mammals (e.g., humans) having or at risk of developing a disease or condition characterized by inflammation and / or degeneration of tissue. For example, provided herein are mesenchymal stem cells (MSCs) that express tissue-targeting antigen receptors (e.g., chimeric antigen receptors) that can exert immunosuppressive effects in targeted tissues, and methods of using such MSCs.

The purpose of the present invention is to provide a nucleic acid molecule, a vector, recombinant cells, and a drug for treating a central nervous system disease which is likely to migrate into the central nervous system. The nucleic acid molecule according to the present invention comprises a base sequence encoding a fusion protein of: an anti-transferrin receptor (TfR) antibody or an antigen-binding fragment thereof; and a protein which functions in the central nervous system.

The present invention provides a composition for treating diseases or symptoms related to the hair cycle (such as hair cycle-related diseases). [Solution] A composition for treating alopecia comprising a compound for miR-520d-5p polynucleotide upregulation, wherein the compound for miR-520d-5p polynucleotide upregulation is selected from the group consisting of vancomycin, metoprolol, benzethonium, chlorpropamide, betaxolol, colistin, oxprenolol, ethacrine, bisoprolol, alexidine, bumetanide, and glycopyrrolate. The compound for miR-520d-5p polynucleotide upregulation can revert hair cycle-related genes to the wild type in dermal papilla cells, skin-derived precursor cells, bulge stem cells, or stem cells such as iPS cells that can differentiate into such cells.